EORTC at the EU Health and Technology Assessment (HTA) Conference
EORTC – European Organisation for Research and Treatment of Cancer shared a post on LinkedIn:
“Today, at the EU Health and Technology Assessment (HTA) Conference, EORTC CEO Denis Lacombe contributed to a key panel discussion on the future of the EU HTA Regulation.
Denis emphasised:
“The EU’s HTA regulation offers a framework for collaborative assessment, potentially speeding up patient access to new treatments. However, it doesn’t address treatment optimisation or post-licensing studies, often handled by academic sponsors. Healthcare systems that balance expanding and optimising therapies will best ensure patient-centricity.”
This perspective underscores the importance of integrating academic research into HTA processes to truly serve patient needs.”
More post featuring European Organisation for Research and Treatment of Cancer on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023